Navigation Links
ChanTest to Highlight Expanded Ion Channel and GPCR Services and Cell Lines, Including FDA Critical Path Safety Profiling Tools at ToxExpo, Booth 3056
Date:3/10/2009

- Company to host seminar Tuesday, March 17, 2009, from 8:30 to 9:30 AM in Room 337

CLEVELAND, Ohio, March 10 /PRNewswire/ -- ChanTest, the leading expert in ion channels and GPCRs (G-protein coupled receptors) - key to drug discovery, development, and safety - will feature the latest in its expanding line of services and reagents at booth 3056 at the Society of Toxicology conference March 15-19, in Baltimore, Maryland. ChanTest's growing catalog, comprising 86 ion channel and 48 GPCR cell lines, can be arranged into panels for preclinical testing, consistent with the FDA and ICH S7A safety guidance, to assess a drug's risk for unintended cardiac (ICH S7B) and CNS (ICH S7A) effects. ChanTest also offers channel panels and high-throughput screening to assess the efficacy and safety of compounds as therapeutic targets for a number of diseases and disorders including cancer, cardiovascular, metabolic/gastrointestinal, pain/inflammation, psychiatric disorder, pulmonary/respiratory, and seizure/convulsion. ChanTest has validated these panels against the "gold standard" manual patch clamp assay to ensure that results from early screens will correlate with GLP study results that are required for IND submission.

For customers that prefer to do their own testing in house, ChanTest offers its catalog of validated ion channel and GPCR replicating cell lines for sale as reagents. Thirty-six division-arrested GPCR cell lines (EZCells (TM)) are also available.

"ChanTest is well known as the leader in preclinical cardiac safety testing. We were the first to prove hERG as the target for adverse cardiac events linked to Seldane (terfenadine), Propulsid (cisapride), and Nizoral (ketoconazole), and the pioneer in functional, cell-based ion channel testing to predict cardiac side effects produced by non-cardiac drugs," said ChanTest Chief Executive Officer, Dr. Arthur (Buzz) Brown, M.D., Ph.D. "As the knowledge base has exp
'/>"/>

SOURCE ChanTest
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Stanford study highlights cost-effective method of lowering heart disease risks
2. REACH Registry Highlights That Patients With Peripheral Arterial Disease (PAD) Suffer High Rates of Heart Attack, Stroke, Hospitalization, and Death
3. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
4. Other highlights in the September 11 JNCI
5. Medicare Prescription Drug Benefit, Nonprofit Hospitals, Ambulatory Surgery Centers, Statistical Methods, and Pay-For-Performance Highlighted In the Latest INQUIRY Journal
6. Scientists highlight benefits of genetic research in sport, but warn of ethical concerns
7. A New Interactive Consumer Experience Highlighting Successful Weight Loss Strategies is Coming to a Mall Near You
8. NEWSWEEK International Editions: Highlights and Exclusives, Oct. 1, 2007 Issue
9. Launch of New Educational Campaign, Spread the Word - NOT the Flu!, Aims to Highlight Importance of Influenza Vaccination
10. Georgia Pecans Fit!: New Campaign Highlights Health Benefits, Recipes, Web Site
11. Highlights from the October 2007 Journal of the American Dietetic Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... Today, Digital-Signage-China.com adds 2 new items to its ... signage media player promotion for Dec. 2014. , The ... wave in April, and this promotion will help to expand ... desired models on our website, she/he can contact us with ... new models come in the latest designs, and they actually ...
(Date:11/27/2014)... The American Society for Clinical Pathology (ASCP) announced ... honor of World AIDS Day 2014. On Nov. 25, ASCP ... icon and infographic designed to generate public awareness about World ... , ASCP has asked members to replace their Facebook, Twitter, ... Tested. Find a cure.” icon and share the accompanying infographic ...
(Date:11/27/2014)... Cambrionix Ltd today announced that it ranked number 10 ... the 50 fastest-growing technology companies in the UK. Rankings ... years. Cambrionix Ltd grew 2989 percent during this period. ... of Cambridgeshire and East and first in the sector of ... recognition of the hard work put in by our team ...
(Date:11/27/2014)... York (PRWEB) November 27, 2014 ... have been filed in a consolidated litigation now ... reports. , Documents recently updated in the ... included in the state proceeding, all of which ... disorder and other psychiatric conditions. Many of the ...
(Date:11/27/2014)... PA (PRWEB) November 27, 2014 In order ... inventor from Sharpes, Fla., designed an easy way to avoid ... it/them. , He then created a prototype of the patent-pending ... or lower a toilet seat and/or lid in a more ... prevents the spread of germs. Overall, it promotes good hygiene ...
Breaking Medicine News(10 mins):Health News:Digital-Signage-China.com Offers Big Discounts On Its New Digital Signage Media Players 2Health News:ASCP Launches Social Media Campaign in Honor of World AIDS Day 2Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 2Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 3Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 4Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 3Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 4
... all think we know a lot about vitamins, minerals ... studies have created confusion regarding their importance; a simple ... is that “Vitamins and other nutrients, including calcium and ... ,Stressing the point is Dr. Joseph C. Maroon, ...
... forefront of the mission to translate discoveries in basic sciences ... schools to have been chosen to receive a collective grant ... ,"The gap between basic biology and medical practice is ... education at the School of Medicine and principal investigator of ...
... in Russia has been witness to the death of more ... has hit the south of Russia.// ,According to ... Jan 25 and Feb 1, almost 350,000 birds have died ... 76,000 at the Makhachkalinskaya farm between Feb. 6 and Feb. ...
... response of MPs in favor of the proposed smoking ban in ... would be imposed by the summer of next year in the ... 184 has been achieved when the issue of smoking ban extension ... Following implementation of the law, both the public and club/pub workers ...
... mammalian protein called Rad9 could hold the key to killing ... at Washington University School of Medicine in St. Louis. Rad9 ... DNA, but it is now fund to be a "repairman" ... ,That is why reserachers are now ...
... the world's most common liver infection. It spreads easily and ... ,It causes liver cirrhosis, // liver failure and liver ... of the world's population, has been infected with the hepatitis ... are chronic carriers of the virus. Normally in case of ...
Cached Medicine News:Health News:Never undermine the importance of calcium and Vitamin D 2Health News:Getting Basic Science to Work For Medicine 2Health News:Switching Off Protein Could Play Key Role In Success Of Radiation Therapy For Cancer 2
(Date:11/26/2014)... Nov. 26, 2014  Aethlon Medical, Inc. (OTCQB:AEMD), announced ... to raise approximately $3.3 million at a price of ... one institutional healthcare focused investor. Each unit consists of one ... share purchase warrant. Each whole warrant entitles the holder ... $0.30 for a period of five years from closing.  ...
(Date:11/26/2014)... , Nov. 26, 2014 Lexicon ... announced the completion of previously announced concurrent financing ... After fees and estimated offering expenses, Lexicon anticipates ... transactions.  The transactions consisted of: , ... stock, pursuant to a registration statement that has ...
(Date:11/26/2014)... Investor-Edge has initiated coverage on the following equities: ... (NASDAQ: HZNP ), Endocyte Inc. (NASDAQ: ... and Theravance Inc. (NASDAQ: THRX ). Free research ... . On Tuesday, November 25, 2014, the NASDAQ ... Average edged 0.02% lower, to finish the day at 17,814.94, ...
Breaking Medicine Technology:Aethlon Medical Announces $3.3 Million Equity Investment 2Aethlon Medical Announces $3.3 Million Equity Investment 3Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5
... IRVINE, Calif., June 12 Masimo (Nasdaq: ... Motion and Low-Perfusion pulse oximetry, announced today that three ... of Masimo PVI as a noninvasive and continuous measure ... week at the European Society of Anaesthesiology (ESA) Annual ...
... Safety and Biologic Activity Data Reviewed in End of Phase ... VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a ... treatment of cardiovascular and metabolic disease, announced today that an ... VIA-2291 (atreleuton), was recently held with the U.S. Food and ...
Cached Medicine Technology:New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 2New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 3New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 4New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 5New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 6VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 2VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 3VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 5
Classic black cast boot with unisex styling...
... cast boot specially lasted for fiberglass ... rocker sole for easy ambulation! ,The ... narrow last so it fits better ... and with our stretchable upper, a ...
The Multi-Purpose Medical-Surgical Shoe...
The Low Profile boot provides a durable canvas upper, with an open toe and heel. Padded EVA insole protection. The lower outsole compensates for casting thickness. Available in six unisex sizes....
Medicine Products: